THERAPEUTICS
Benefits of tight blood pressure control to prevent diabetes complications were not sustained
| The first 150 words of the full text of this article appear below. |
R R Holman
Dr R R Holman, Diabetic Trials Unit, Oxford, UK; rury.holman@dtu.ox.ac.uk
STUDY DESIGN
randomised controlled trial (Hypertension in Diabetes Study) within the UK Prospective Diabetes Study (UKPDS). Current Controlled Trials ISRCTN75451837 [controlled-trials.com] .
{concealed}*.
blinded (outcome adjudication committee).
STUDY QUESTION
{20}* centres in the UK.
1148 patients {mean age 56 y, 56% men}* with type 2 diabetes who were already participating in the UKPDS and had hypertension. Exclusion criteria included need for strict BP control or β-blockade and severe illness.
tight BP control with either an angiotensin-converting enzyme (ACE) inhibitor (captopril,
50 mg twice/d, n = 400) or a β-blocker (atenolol,
100 mg once/d, n = 358), or less-tight BP control without use of an ACE inhibitor or a β-blocker (n = 390). BP targets were <150/85 mm Hg in the tight-control group and <180/105 mm Hg in the less-tight-control group.
7 composite outcomes (any diabetes-related end point, diabetes-related death, death from any
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
